BCYC — Bicycle Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $949.67m
- $453.95m
- $26.98m
Annual income statement for Bicycle Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 13.8 | 10.4 | 11.7 | 14.5 | 27 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 40.1 | 62.4 | 77.3 | 131 | 217 |
| Operating Profit | -26.3 | -52 | -65.6 | -117 | -190 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -30.9 | -51.7 | -68.5 | -114 | -179 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -30.6 | -51 | -66.8 | -113 | -181 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -30.6 | -51 | -66.8 | -113 | -181 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -30.6 | -51 | -66.8 | -113 | -181 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.77 | -2.66 | -2.67 | -3.8 | -5.08 |